Known targets — ChEMBL curated mechanism
ACHEBDKRB2CHRM1CHRM2CHRM3CHRNA1CHRNB1CHRNDCHRNECHRNGGUCY1A1GUCY1A2GUCY1B1GUCY1B2NAMPTPTAFRSLC10A2SLC6A2SLC6A3TACR1dacAdacBdacCftsImrcAmrcBmrdA
The experimentally established mechanism targets of Phenformin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 known ✓ | P23975 | 1/20 | 0.93 |
| ▸ | SLC6A3 known ✓ | Q01959 | 1/20 | 0.93 |
| ▸ | LMNA | P02545 | 3/20 | 0.93 |
| ▸ | HIF1A | Q16665 | 3/20 | 0.93 |
| ▸ | TSHR | P16473 | 2/20 | 0.93 |
| ▸ | SLC22A2 | O15244 | 1/20 | 0.93 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.93 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.93 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.93 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.93 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.93 |
| ▸ | HTR2B | P41595 | 1/20 | 0.93 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.93 |
| ▸ | MAPT | P10636 | 1/20 | 0.90 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.90 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.90 |
| ▸ | CA12 | O43570 | 2/20 | 0.58 |
| ▸ | CA1 | P00915 | 2/20 | 0.58 |
| ▸ | CA2 | P00918 | 2/20 | 0.58 |
| ▸ | CA9 | Q16790 | 2/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Phenformin SCHEMBL8425 | 0.96 | LMNA (1.00) | LMNAHIF1ATSHRSLC22A2SLC22A1 | |
| Phenformin SCHEMBL10325620 | 0.96 | LMNA (1.00) | LMNAHIF1ATSHRSLC22A2SLC22A1 | |
| Phenformin SCHEMBL136512 | 0.96 | LMNA (1.00) | LMNAHIF1ATSHRSLC22A2SLC22A1 | |
| SCHEMBL19770321 | 0.82 | HIF1A (0.74) | LMNAHIF1ATSHRSLC22A2SLC22A1 | |
| SCHEMBL28524333 | 0.82 | HIF1A (0.74) | LMNAHIF1ATSHRSLC22A2SLC22A1 | |
| [11C]Phenethylguanidine SCHEMBL837645 | 0.81 | HTR3A (0.80) | LMNAHIF1ATSHRSLC22A2SLC22A1 | |
| SCHEMBL23366564 | 0.79 | TSHR (0.69) | LMNAHIF1ATSHRSLC22A2SLC22A1 | |
| SCHEMBL1736065 | 0.77 | TAAR1 (0.67) | LMNAHIF1ATSHRSLC22A2SLC22A1 | |
| SCHEMBL1736064 | 0.77 | TAAR1 (0.67) | LMNAHIF1ATSHRSLC22A2SLC22A1 | |
| [11C]Phenethylguanidine SCHEMBL28305963 | 0.76 | HTR3A (0.71) | LMNAHIF1ATSHRSLC22A2SLC22A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12453713-B2 | Liquid formulation to treat a corneal tissue | VISION ENGINEERING ITALY SRL (IT) | 2025-10-28 | — | — | US | disclosed |
| CN-114126650-B | Liquid formulation, in particular for the treatment of corneal tissue | 意大利视觉工程有限公司 | 2024-02-09 | — | — | CN | disclosed |
| US-20230131004-A1 | LIQUID FORMULATION, IN PARTICULAR TO TREAT A CORNEAL TISSUE | VISION ENGINEERING ITALY SRL (IT) | 2023-04-27 | — | — | US | disclosed |
| US-20220107328-A1 | METHODS OF TREATING LIVER DISEASES | CAMP4 THERAPEUTICS CORPORATION | 2022-04-07 | — | — | US | disclosed |
| CN-114126650-A | Liquid preparation, in particular for the treatment of corneal tissue | 意大利视觉工程有限公司 | 2022-03-01 | — | — | CN | disclosed |
| CN-114097815-A | Application of medical compound with amidine skeleton in resisting plant pathogenic bacteria | 兰州大学 | 2022-03-01 | — | — | CN | disclosed |
| WO-2021040441-A1 | METHOD FOR PREPARING BIGUANIDE-BASED COMPOUND | 주식회사 하임바이오 | 2021-03-04 | — | — | WO | disclosed |
| EP-3482753-B1 | COMPOSITIONS AND THEIR USES FOR THE TREATMENT OF DIABETES AND RELATED CONDITIONS BY CONTROLLING BLOOD GLUCOSE LEVEL | PHARNEXT (FR) | 2021-01-27 | — | — | EP | disclosed |
| WO-2021009623-A1 | LIQUID FORMULATION, IN PARTICULAR TO TREAT A CORNEAL TISSUE | VISION ENGINEERING ITALY SRL (IT) | 2021-01-21 | — | — | WO | disclosed |
| US-20200222409-A1 | COMPOSITIONS, METHODS AND USES FOR THE TREATMENT OF DIABETES AND RELATED CONDITIONS BY CONTROLLING BLOOD GLUCOSE LEVEL | PHARNEXT (FR) | 2020-07-16 | — | — | US | disclosed |
| US-20160206603-A1 | COMPOSITION COMPRISING TORASEMIDE AND BACLOFEN FOR TREATING NEUROLOGICAL DISORDERS | PHARNEXT (FR) | 2016-07-21 | — | — | US | disclosed |
| EP-3038614-A1 | COMPOSITION COMPRISING TORASEMIDE AND BACLOFEN FOR TREATING NEUROLOGICAL DISORDERS | Pharnext (FR) | 2016-07-06 | — | — | EP | disclosed |
| CN-105744932-A | Folded biosensor | 法耐斯特公司 | 2016-07-06 | — | — | CN | disclosed |
| US-20150231123-A1 | COMPOSITIONS, METHODS AND USES FOR THE TREATMENT OF DIABETES AND RELATED CONDITIONS BY CONTROLLING BLOOD GLUCOSE LEVEL | PHARNEXT (FR) | 2015-08-20 | — | — | US | disclosed |
| US-20150140123-A1 | Protein expression analyses for identifying genotoxic compounds | MERCK PATENT GMBH (DE) | 2015-05-21 | — | — | US | disclosed |
| WO-2015028659-A1 | COMPOSITION COMPRISING TORASEMIDE AND BACLOFEN FOR TREATING NEUROLOGICAL DISORDERS | PHARNEXT (FR) | 2015-03-05 | — | — | WO | disclosed |
| US-20140038927-A1 | COMPOSITIONS FOR TREATING NEUROLOGICAL DISORDERS | PHARNEXT (FR) | 2014-02-06 | — | — | US | disclosed |
| US-20130302815-A1 | Screening Method | ACADEMISCH ZIEKENHUIS LEIDEN also acting under the name LEIDEN UNIVERSITY MEDICAL CENTER (NL) | 2013-11-14 | — | — | US | disclosed |
| EP-2616484-A2 | SCREENING METHOD | Universiteit Leiden (NL) | 2013-07-24 | — | — | EP | disclosed |
| WO-2012035120-A2 | SCREENING METHOD | UNIVERSITEIT LEIDEN (NL) | 2012-03-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220107328-A1 | METHODS OF TREATING LIVER DISEASES | PNPLA2, LIPC, PNLIP | SLC6A2 2002/4885SLC6A3 1786/4885LMNA 459/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.